Context Therapeutics Inc.
CNTX
$1.09
$0.032.83%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 0.65% | 13.13% | 11.67% | 9.85% | 10.67% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -43.26% | 215.96% | 44.61% | -37.83% | 202.59% |
| Operating Income | 43.26% | -215.96% | -44.61% | 37.83% | -202.59% |
| Income Before Tax | 44.48% | -291.55% | -24.80% | 50.62% | -197.20% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 44.48% | -291.55% | -24.80% | 50.62% | -197.20% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 44.48% | -291.55% | -24.80% | 50.62% | -197.20% |
| EBIT | 43.26% | -215.96% | -44.61% | 37.83% | -202.59% |
| EBITDA | 43.28% | -216.08% | -44.60% | 37.85% | -202.69% |
| EPS Basic | 53.07% | -126.10% | 79.06% | 90.38% | 41.04% |
| Normalized Basic EPS | 53.10% | -126.56% | 79.04% | 90.38% | 41.04% |
| EPS Diluted | 53.07% | -126.10% | 79.06% | 80.33% | 41.04% |
| Normalized Diluted EPS | 53.10% | -126.56% | 79.04% | 90.38% | 41.04% |
| Average Basic Shares Outstanding | 18.27% | 73.20% | 496.18% | 413.15% | 404.07% |
| Average Diluted Shares Outstanding | 18.27% | 73.20% | 496.18% | 413.15% | 404.07% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |